Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure more widespread availability of the drug 2-HDP.

We are pleased to see promising results from the Queen's University Belfast study into the novel drug known as 2-Hydrazino-4,6-dimethylpyrimidine (2-HDP). This demonstrates the strength of the United Kingdom’s clinical research environment and the important role played by patient organisations such as Diabetes UK.

This is early-stage research and further studies, including clinical trials, are required before it can be made available to patients. We look forward to seeing how it progresses.

In the UK, medicines need to have a licence before they can be marketed. These are granted by the Medicines and Healthcare products Regulatory Agency (MHRA). Licences confirm the health condition the medicine should be used for and the recommended dosage. To get a licence, the manufacturer of the medicine has to provide evidence which shows that the medicine is safe and effective enough to be used for a specific condition and for a specific group of patients, and that they can manufacture the medicine to the required quality.

The anticipated licensing timelines for 2-HDP are currently unknown, but the MHRA and the National Institute for Health and Care Excellence liaise closely with pharmaceutical companies on their plans with respect to regulatory approval in the UK to support timely access to clinically and cost-effective licensed medicines for National Health Service patients.